Skip to main content

Table 1 Clinicopathologic and molecular characteristics of MPA and LA cases

From: A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients

Variables

MPA (n = 55)

LA(n = 76)

χ2

p

Gender

  

0.518

0.485

 Female

24(43.6%)

38(50.0%)

  

 Male

31(56.4%)

38(50.0%)

  

Age(years)

  

7.452

0.008**

> 65

20(36.4%)

46(60.5%)

  

≤ 65

35(63.6%)

30(39.5%)

  

Smoking history

  

0.191

0.723

 Ever

26(47.3%)

33(43.4%)

  

 Never

29(52.7%)

43(56.6%)

  

Tumor size(cm)

  

0.058

0.851

 > 3.0

17(30.9%)

25(32.9%)

  

 ≤ 3.0

38(69.1%)

51(67.1%)

  

Lymphovascular invasion

  

1.645

0.225

 Present

17(30.9%)

16(21.1%)

  

 Absent

38(69.1%)

60(78.9%)

  

Tumor differentiation

  

0.179

0.835

 Well/moderate

43(78.2%)

57(75.0%)

  

 Poor

12(21.8%)

19(25.0%)

  

N status

  

4.291

0.03*

 N0

31(56.4%)

56(73.7%)

  

 N1/N2

24(43.6%)

20(26.3%)

  

Pleural invasion

  

4.117

0.036*

 Present

15(27.3%)

10(13.2%)

  

 Absent

40(72.7%)

66(86.8%)

  

Stage

  

5.701

0.024*

 I/II

47(85.5%)

51(67.1%)

  

 III/IV

8(14.5%)

25(32.9%)

  

Mutation status

    

EGFR mutation

42(76.4%)

42(55.3%)

6.175

0.016*

EML4-ALK fusion

3(5.5%)

1(1.3%)

1.846

0.309

ROS1 fusion

6(10.9%)

1(1.3%)

5.806

0.041*

  1. MPA micropapillary lung adenocarcinoma, LA lung adenocarcinoma without micropapillary component
  2. *p<0.05; **p<0.01 compared with LA